Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

...

194

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable solution	883,480 L.L
N02CD01	AIMOVIG	BioTech	Erenumab - 70mg/ml	70mg/ml	Injectable solution	35,423,371 L.L
A10AB04	HUMALOG	BioTech	Insulin lispro - 100IU/ml	100IU/ml	Injectable suspension	1,988,887 L.L
N02CD02	EMGALITY	BioTech	Galcanezumab - 120mg/ml	120mg/ml	Injectable suspension	37,250,732 L.L
L01FX24	TECVAYLI	BioTech	Teclistamab - 90mg/ml	90mg/ml	Injectable solution	L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable suspension	1,503,312 L.L
L01FX07	BLINCYTO	BioTech	Blinatumomab - 35mcg	35mcg	Injectable lyophilised powder for solution+stabilizer	L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
M05BX04	PROLIA	BioTech	Denosumab - 60mg/ml	60mg/ml	Injectable solution	21,603,638 L.L
H01AC01	CINNATROPIN	BioTech	Somatropin recombinant - 10mg/1.5ml	10mg/1.5ml	Injectable solution	L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
M05BX04	XGEVA	BioTech	Denosumab - 120mg	120mg	Injectable solution	33,545,669 L.L
L04AC05	STELARA	BioTech	Ustekinumab - 45mg	45mg	Injectable solution	L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
M05BX06	EVENITY	BioTech	Romosozumab - 105mg/1.17ml	105mg/1.17ml	Injectable solution	56,729,091 L.L
A10AB06	APIDRA SOLOSTAR	BioTech	Insulin glulisine - 100IU/ml	100IU/ml	Injectable solution	3,942,834 L.L
A10AB06	APIDRA	BioTech	Insulin glulisine - 100IU/ml	100IU/ml	Injectable solution	2,221,372 L.L
A10AD01	HUMULIN 70/30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	701,486 L.L
A10AD01	JUSLINE	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	401,809 L.L
S01LA04	LUCENTIS	BioTech	Ranibizumab - 10mg/ml	10mg/ml	Injectable solution	51,255,093 L.L
D11AH05	DUPIXENT	BioTech	Dupilumab - 300mg	300mg	Injectable solution	L.L
A10AD01	MIXTARD 30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	752,552 L.L
S01LA05	EYLEA	BioTech	Aflibercept - 40mg/ml	40mg/ml	Injectable solution	65,161,855 L.L
L01FC01	DARZALEX	BioTech	Daratumumab - 400mg/20ml	400mg/20ml	Injectable concentrate for solution	L.L
A10AD01	MIXTARD 30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	752,552 L.L
S01LA05	EYLEA	BioTech	Aflibercept - 8mg/0.07ml	114.3mg/ml	Injectable solution	78,332,038 L.L
L04AA23	TYSABRI	BioTech	Natalizumab - 300mg/15ml	300mg/15ml	Injectable concentrated solution	L.L
A10AD04	HUMALOG MIX 50 KWIKPEN	BioTech	Insulin lispro solution - 50%, Insulin lispro protamine suspension - 50%	100IU/ml	Injectable suspension	3,950,897 L.L
S01LA06	BEOVU	BioTech	Brolucizumab - 120mg/ml	120mg/ml	Injectable solution	42,752,178 L.L
A10AD04	HUMALOG MIX 25 KWIKPEN	BioTech	Insulin lispro solution - 25%, Insulin lispro protamine suspension - 75%	100IU/ml	Injectable suspension	3,950,897 L.L

...

194